Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R VanDevanter

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 15, 2024
Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosisE T Zemanick, I Emerman, M McCreary, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 26, 2017
Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosisD R VanDevanter, S L Heltshe, J Spahr, et al.
Nature|July 6, 2000
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisC K Stover, P Warrener, D R VanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2020
Building global development strategies for cf therapeutics during a transitional cftr modulator eraN Mayer-Hamblett, S van Koningsbruggen-Rietschel, D P Nichols, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 15, 2024
Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosisE T Zemanick, I Emerman, M McCreary, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 26, 2017
Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosisD R VanDevanter, S L Heltshe, J Spahr, et al.
Nature|July 6, 2000
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisC K Stover, P Warrener, D R VanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2020
Building global development strategies for cf therapeutics during a transitional cftr modulator eraN Mayer-Hamblett, S van Koningsbruggen-Rietschel, D P Nichols, et al.
Pageof 4